Science & Innovation Theater presented by Sanofi

Sunday, October 20, 2024

12:45 PM - 1:45 PM

Location: Exhibit Hall A3/B3

CE: N/A

Sponsored By

Speaker(s)

Jay Raval, MD

Associate Professor, Vice Chair, Director
University of New Mexico Department of Pathology
Albuquerque, New Mexico, United States

Disclosure information not submitted.
LG

Leticia Gonzalez

Disclosure information not submitted.

Outcomes of Treatment with CABLIVI (caplacizumab-yhdp)

Join us for an engaging discussion on aTTP/iTTP and available treatment options for the disease

Learning Objectives:
• Provide an overview of aTTP/iTTP, including pathophysiology, epidemiology, patient presentation, disease burden, and diagnosis
• Understand the importance of rapid diagnosis and immediate treatment due to acute nature and high mortality of aTTP/iTTP disease if left untreated
• Discuss available treatment options for aTTP/iTTP
• Review results of US and international real-world studies on aTTP/iTTP
• Review the ISTH Guidelines and their recommendation on Diagnosis and Treatment Approaches for TTP.
• Discuss coverage and reimbursement for CABLIVI.
• Q&A Session

Speakers:
Jay Raval, MD; Associate Professor Senior Director, Transfusion Medicine and Therapeutic Pathology University of New Mexico Albuquerque, NM

Leticia Gonzalez, Director of Institutional Accounts Teams at Sanofi